亞盛醫藥-B(06855.HK)再獲授權人UNITY里程碑付款，候選抗衰老藥物“UBX1325”臨牀開發迅速推進
格隆匯7月29日丨亞盛醫藥-B(06855.HK)發佈公吿，公司全球獲授權人UNITY Biotechnology, Inc.(“UNITY”，NASDAQ:UBX)報吿在研Bcl-xL抑制化合物UBX1325治療晚期血管性眼病患者的I期臨牀試驗獲正面數據，並已完成後續IIa期臨牀試驗的首例患者給藥。UBX1325來自亞盛醫藥授權UNITY用於針對年齡相關疾病藥物臨牀開發的候選藥物BM-962。根據此前雙方達成的授權許可協議的條款，公司將獲得以UNITY普通股形式支付的200萬美元里程碑付款。
UBX1325是一種Bcl-xL小分子抑制劑，是首個進入眼科臨牀試驗的抗衰老藥物。UBX1325採用靶向抑制衰老細胞生存所依賴的蛋白質功能，有望為抗VEGF療法提供一種有價值的替代或輔助治療選擇。據UNITY發佈的新聞稿顯示1，在評估UBX1325對於治療晚期糖尿病性黃斑水腫(DME)或濕性年齡相關性黃斑變性(wet-AMD)且抗VEGF治療無效的患者的安全性的I期臨牀試驗中，大多數接受UBX1325單次注射治療的DME或wet-AMD患者表現出多項關鍵性臨牀指標的快速改善。UBX1325在該患者羣體中具有良好的耐受性和安全性，未觀察到治療相關不良事件或限制性毒性劑量(DLT)。此外，治療DME的IIa期臨牀試驗已完成首例患者給藥，用於評估UBX1325在更廣泛的DME患者羣體中的安全性和有效性。
亞盛醫藥於2016年與UNITY達成戰略授權許可協議，UNITY獲授權可對亞盛醫藥的Bcl-2系列化合物進行篩選，以用於在年齡相關疾病領域的開發。亞盛醫藥化合物庫中的BM-962被UNITY選為用於UBX1325研發的化合物。根據授權許可協議，亞盛醫藥擁有該化合物的大中華地區權益，未來可能計劃和UNITY成立合資公司，共同在中國市場開發及商業化該化合物。UNITY致力於通過延緩、阻止乃至逆轉和衰老有關的疾病，從而延長人類的健康壽命，其研究主要集中在基於清除衰老細胞的抗衰老治療藥物的開發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
